Spots Global Cancer Trial Database for Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

Official Title: Positron Emission Tomography Imaging of Bone in Patients With Metastatic Prostate Cancer - A Pilot Study Evaluating Treatment Response

Study ID: NCT00392938

Conditions

Metastatic Cancer

Prostate Cancer

Interventions

antiandrogen therapy

docetaxel

C-11 acetate PET scan

F-18 FDG PET scan

Tc-99m bone scan

CT scan of the chest, abdomen and pelvis

Study Description

Brief Summary: RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.

Detailed Description: OBJECTIVES: Primary * Correlate pre-treatment and 3-month post-treatment carbon-11 (\^11C) acetate and fludeoxyglucose F 18 positron emission tomography (\^18F-FDG PET) images with changes in clinical response measures in patients with bone-dominant metastatic prostate cancer. Secondary * Compare \^11C acetate and \^18F-FDG PET scanning results with bone scintigraphy in these patients to determine which best predicts clinical response. * Correlate changes in \^11C acetate and \^18F-FDG PET with changes in prostate-specific antigen level. * Correlate changes in \^11C acetate and \^18F-FDG PET with clinical symptom parameters (pain scale scores and analgesic usage scales). * Correlate \^11C acetate and \^18F-FDG PET scan response with clinical time to progression. * Determine if PET scan response can predict duration of progression-free survival. OUTLINE: This is a pilot study. Patients are stratified according to hormone response (sensitive \[stratum 1\] vs refractory \[stratum 2\]). Patients undergo carbon-11 acetate and fludeoxyglucose F 18 positron emission tomography imaging prior to and 3 months after initiation of either androgen-deprivation therapy (stratum 1) or docetaxel (stratum 2). Pain and quality of life are assessed at baseline and at 3 months. Patients are followed every 3 months for up to 5 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.